Oddo BHF Asset Management Sas Sells 36,137 Shares of Twist Bioscience Corporation $TWST

Posted by Geri Gentry on Jun 17th, 2026

Oddo BHF Asset Management Sas reduced its stake in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 21.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 135,650 shares of the company’s stock after selling 36,137 shares during the quarter. Oddo BHF Asset Management Sas’ holdings in Twist Bioscience were worth $4,303,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of TWST. Quarry LP bought a new stake in Twist Bioscience in the 3rd quarter valued at $28,000. Smartleaf Asset Management LLC increased its holdings in Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after acquiring an additional 442 shares during the last quarter. Strategic Advocates LLC increased its holdings in Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after acquiring an additional 906 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after acquiring an additional 571 shares during the last quarter. Finally, National Bank of Canada FI bought a new position in shares of Twist Bioscience during the 3rd quarter valued at approximately $46,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TWST shares. Robert W. Baird increased their target price on Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Canaccord Genuity Group started coverage on Twist Bioscience in a research report on Monday. They set a “buy” rating and a $90.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Barclays increased their target price on Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Finally, Leerink Partners set a $80.00 target price on Twist Bioscience in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.60.

Read Our Latest Report on TWST

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $84.95 on Wednesday. The company has a 50 day moving average price of $60.98 and a 200-day moving average price of $48.30. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $86.94. The company has a market capitalization of $5.29 billion, a PE ratio of -63.87 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The company had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. During the same period in the prior year, the firm posted ($0.66) EPS. The business’s revenue was up 19.3% on a year-over-year basis. As a group, equities analysts forecast that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, Director Melissa A. Starovasnik sold 1,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $51.00, for a total transaction of $51,000.00. Following the transaction, the director directly owned 25,722 shares in the company, valued at $1,311,822. This represents a 3.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Emily M. Leproust sold 8,061 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $65.29, for a total transaction of $526,302.69. Following the transaction, the chief executive officer owned 858,887 shares in the company, valued at approximately $56,076,732.23. The trade was a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 33,170 shares of company stock worth $1,948,964 over the last quarter. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

(Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.